StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.
Moleculin Biotech Stock Performance
Shares of NASDAQ MBRX opened at $2.55 on Friday. Moleculin Biotech has a 1-year low of $2.12 and a 1-year high of $15.75. The firm’s 50-day moving average price is $2.49 and its 200-day moving average price is $3.54.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, analysts predict that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- 3 Warren Buffett Stocks to Buy Now
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- The 3 Best Retail Stocks to Shop for in August
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.